Demis Hassabis Is Doing to Pharma What He Did to Chess #AIBreakthrough #Biotech

Ajouté : 2026-05-17

[00:00:00]Isomorphic Labs, $2.1 billion series B.

[00:00:05]And the man who built it just said publicly that his goal is to quote "solve all diseases." That number alone isn't the story. The story is who showed up to this round and what it signals about where the real money thinks drug discovery is heading. Thrive Capital led it. But then look at what happened next.

[00:00:27]Alphabet and GV, who were already in from the first round, came back. They didn't just hold their position, they doubled down, and they brought new money with them. MGX out of Abu Dhabi, Temasek from Singapore, Capital G, and the UK's own sovereign AI fund. When two sovereign wealth funds from different continents decide the same bet is worth making at the same time, that's not a coincidence. That's a coordinated read on where AI is actually going. So, what does Isomorphic actually do? The company is building an AI platform that designs drugs from scratch. Not searching a database. Not running simulations on existing molecules. Designing new ones.

[00:01:12]Small molecules, antibodies, RNA therapeutics, the full architecture of modern medicine. Their engine is called ISO DDE.

[00:01:23]And according to the CEO, it's already produced breakthrough molecules across active drug programs. Here's what that means for the economics. Pharma's current model spends a billion dollars and 15 years just to get one drug to a trial.

[00:01:39]Isomorphic's thesis is that AI can collapse that timeline. Design faster, fail cheaper, bet bigger on the candidates that actually matter. That is not a science pitch. That is a margin pitch. And investors understand margin.

[00:01:56]The person behind this is Demis Hassabis. He built DeepMind.

[00:02:01]He oversaw AlphaFold, the AI that cracked a 50-year biology problem and won a Nobel Prize. He didn't license that research and walk away. He spun out a whole new company to commercialize it, and he just raised $2.1 billion to go further. When someone with that track record says he wants to solve all diseases and sovereign funds across two continents write the check, you pay attention. Subscribe to Fund AI Mentals for the mechanics behind the deals that actually matter.